Shannon G Panther1, Alice M Knotts1, Tamara Odom-Maryon1, Kenneth Daratha1, Teri Woo1, Tracy A Klein1. 1. College of Pharmacy (SGP, AMK), Washington State University, Spokane, Washington, College of Nursing (KD, TAK, TO), Washington State University, Vancouver and Spokane, Washington, and School of Nursing (TW), Pacific Lutheran University, Tacoma, Washington.
Abstract
OBJECTIVE: This study examines off-label medication prescribing use and trends in children on Medicaid with ADHD with particular focus on the very young (under age 6 years). METHODS: This was an observational cohort study and retrospective analysis of ADHD medication prescriptions from Oregon Medicaid records (N = 83,190) in 2012. Manufacturer prescribing information was used to determine off-label designation. Children ages 3 to 18 years at the time of prescription who had continuous Medicaid enrollment of at least 10 months during the index year of 2012 were included in the sample frame. RESULTS: Children with ADHD were prescribed off-label medications primarily at the ages of 5 years and younger. Among children ages 3 to 5 years, 91.4% of prescriptions were off-label. After the age of 5 years, the percentage of off-label prescriptions dropped notably to 21%, reflecting the increase in availability of approved medications for the treatment of ADHD starting at age 6 years. In the 3- to 5-year-old age group, specific off-label and concerning medication-related observations included a high frequency of alpha agonist (e.g., guanfacine, clonidine) prescribing; the prescribing of untested formulations such as clonidine patches; prescribing of atomoxetine; and prescribing of large doses of stimulant medications. CONCLUSIONS: Most ADHD drugs prescribed for very young children are off-label, which is concerning owing to lack of safety and efficacy data in this vulnerable population.
OBJECTIVE: This study examines off-label medication prescribing use and trends in children on Medicaid with ADHD with particular focus on the very young (under age 6 years). METHODS: This was an observational cohort study and retrospective analysis of ADHD medication prescriptions from Oregon Medicaid records (N = 83,190) in 2012. Manufacturer prescribing information was used to determine off-label designation. Children ages 3 to 18 years at the time of prescription who had continuous Medicaid enrollment of at least 10 months during the index year of 2012 were included in the sample frame. RESULTS:Children with ADHD were prescribed off-label medications primarily at the ages of 5 years and younger. Among children ages 3 to 5 years, 91.4% of prescriptions were off-label. After the age of 5 years, the percentage of off-label prescriptions dropped notably to 21%, reflecting the increase in availability of approved medications for the treatment of ADHD starting at age 6 years. In the 3- to 5-year-old age group, specific off-label and concerning medication-related observations included a high frequency of alpha agonist (e.g., guanfacine, clonidine) prescribing; the prescribing of untested formulations such as clonidine patches; prescribing of atomoxetine; and prescribing of large doses of stimulant medications. CONCLUSIONS: Most ADHD drugs prescribed for very young children are off-label, which is concerning owing to lack of safety and efficacy data in this vulnerable population.
Entities:
Keywords:
attention deficit disorder; drug prescribing; off-label use; preschool child
Authors: Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser Journal: Pediatrics Date: 2011-10-16 Impact factor: 7.124
Authors: Daniel A Frattarelli; Jeffrey L Galinkin; Thomas P Green; Timothy D Johnson; Kathleen A Neville; Ian M Paul; John N Van Den Anker Journal: Pediatrics Date: 2014-02-24 Impact factor: 7.124
Authors: Laurence Greenhill; Scott Kollins; Howard Abikoff; James McCracken; Mark Riddle; James Swanson; James McGough; Sharon Wigal; Tim Wigal; Benedetto Vitiello; Anne Skrobala; Kelly Posner; Jaswinder Ghuman; Charles Cunningham; Mark Davies; Shirley Chuang; Tom Cooper Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-11 Impact factor: 8.829
Authors: Lauren D Garfield; Derek S Brown; Benjamin T Allaire; Raven E Ross; Ginger E Nicol; Ramesh Raghavan Journal: Am J Public Health Date: 2015-01-20 Impact factor: 9.308
Authors: Susanna N Visser; Melissa L Danielson; Rebecca H Bitsko; Joseph R Holbrook; Michael D Kogan; Reem M Ghandour; Ruth Perou; Stephen J Blumberg Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-11-21 Impact factor: 8.829
Authors: Kimberly E Hoagwood; Kelly Kelleher; Bonnie T Zima; James M Perrin; Scott Bilder; Stephen Crystal Journal: Health Aff (Millwood) Date: 2016-07-01 Impact factor: 6.301
Authors: Susanna N Visser; Melissa L Danielson; Mark L Wolraich; Michael H Fox; Scott D Grosse; Linda A Valle; Joseph R Holbrook; Angelika H Claussen; Georgina Peacock Journal: MMWR Morb Mortal Wkly Rep Date: 2016-05-06 Impact factor: 17.586
Authors: Marco Solmi; Michele Fornaro; Edoardo G Ostinelli; Caroline Zangani; Giovanni Croatto; Francesco Monaco; Damir Krinitski; Paolo Fusar-Poli; Christoph U Correll Journal: World Psychiatry Date: 2020-06 Impact factor: 49.548
Authors: Ann C Childress; Scott H Kollins; Henry C Foehl; Jeffrey H Newcorn; Greg Mattingly; Robert J Kupper; Akwete L Adjei Journal: J Child Adolesc Psychopharmacol Date: 2019-12-03 Impact factor: 2.576
Authors: Andrea L Schaffer; Claudia Bruno; Nicholas A Buckley; Rose Cairns; Melisa Litchfield; Simon Paget; Helga Zoega; Natasha Nassar; Sallie-Anne Pearson Journal: Paediatr Perinat Epidemiol Date: 2022-02-16 Impact factor: 3.103
Authors: Brian J Piper; Christy L Ogden; Olapeju M Simoyan; Daniel Y Chung; James F Caggiano; Stephanie D Nichols; Kenneth L McCall Journal: PLoS One Date: 2018-11-28 Impact factor: 3.240